IlluminOss Medical completes enrollment for first U.S. clinical trial for fracture-repair system

MANNY AVILA, president and CEO of IlluminOss Medical, is shown speaking with Amy O. Berman, vice president, clinical affairs, in the lab. Berman is holding a model of a bone and Avila has the IlluminOss implant that is inserted inside the bone and then hardened using light.

 / PBN FILE PHOTO/ MICHAEL SALERNO
MANNY AVILA, president and CEO of IlluminOss Medical, is shown speaking with Amy O. Berman, vice president, clinical affairs, in the lab. Berman is holding a model of a bone and Avila has the IlluminOss implant that is inserted inside the bone and then hardened using light. / PBN FILE PHOTO/ MICHAEL SALERNO
EAST PROVIDENCE – IlluminOss Medical Inc. said Monday that it has completed enrollment in its first U.S. clinical trial toward U.S. Food and Drug Administration approval of its IlluminOss System, a minimally invasive system to repair bone fractures. The clinical outcomes data collected will allow IlluminOss to submit a DeNovo marketing application to the FDA…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -